--- title: Effects Of Antidepressants On Sexual Functioning In Adults nct_id: NCT00051272 overall_status: COMPLETED phase: PHASE3 sponsor: GlaxoSmithKline study_type: INTERVENTIONAL primary_condition: Major Depressive Disorder (MDD) countries: United States canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00051272.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00051272" ct_last_update_post_date: 2011-03-29 last_seen_at: "2026-05-12T07:12:46.085Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Effects Of Antidepressants On Sexual Functioning In Adults **Official Title:** A Multicenter, Double-blind Randomized Placebo-controlled Comparison of the Effects on Sexual Functioning of Extended-release Bupropion Hydrochloride (300-450mg) and Escitalopram (10-20mg) in Outpatients With Moderate to Severe Major Depression Over an Eight-Week Treatment Period **NCT ID:** [NCT00051272](https://clinicaltrials.gov/study/NCT00051272) ## Key Facts - **Status:** COMPLETED - **Phase:** PHASE3 - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 425 - **Lead Sponsor:** GlaxoSmithKline - **Conditions:** Major Depressive Disorder (MDD) - **Start Date:** 2003-01 - **Completion Date:** 2004-06 - **CT.gov Last Update:** 2011-03-29 ## Brief Summary This study will evaluate the effects of two antidepression medications on sexual functioning. ## Eligibility - **Minimum age:** 18 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: * Primary diagnosis of Major Depressive Disorder (MDD) with current duration lasting 12 weeks but no greater than 2 years. * Subjects must engage in sexual activity that leads to orgasm at least once every two weeks. * Subject must have normal orgasmic function and be willing to discuss with investigator. Exclusion Criteria: * Subjects that have arousal or orgasm dysfunction. * Has previously failed to respond to two adequate trials of antidepressants in past 2 years. * Subject has other unstable medical disorders. * Subject has a positive urine test for illicit drug use at screening. ``` ## Interventions - **Extended-release Bupropion Hydrochloride** (DRUG) ## Primary Outcomes - **Percent of subjects with orgasm dysfunction. Change from baseline in HAMD-17 total score.** ## Secondary Outcomes - **Percent of subjects in remission, HAMD-17. Changes in Sexual functioning Questionnaire. CGI-I and CGI-S. Percent of responders, HAMD-17.** ## Locations (24) - GSK Investigational Site, Phoenix, Arizona, United States - GSK Investigational Site, Scottsdale, Arizona, United States - GSK Investigational Site, Berkeley, California, United States - GSK Investigational Site, Middletown, Connecticut, United States - GSK Investigational Site, Wilmington, Delaware, United States - GSK Investigational Site, Washington D.C., District of Columbia, United States - GSK Investigational Site, Orlando, Florida, United States - GSK Investigational Site, Marietta, Georgia, United States - GSK Investigational Site, Smyrna, Georgia, United States - GSK Investigational Site, Boise, Idaho, United States - GSK Investigational Site, Baton Rouge, Louisiana, United States - GSK Investigational Site, Braintree, Massachusetts, United States - GSK Investigational Site, Piscataway, New Jersey, United States - GSK Investigational Site, New York, New York, United States - GSK Investigational Site, Raleigh, North Carolina, United States - GSK Investigational Site, Cleveland, Ohio, United States - GSK Investigational Site, Oklahoma City, Oklahoma, United States - GSK Investigational Site, Nashville, Tennessee, United States - GSK Investigational Site, Bellaire, Texas, United States - GSK Investigational Site, San Antonio, Texas, United States - GSK Investigational Site, San Antonio, Texas, United States - GSK Investigational Site, San Antonio, Texas, United States - GSK Investigational Site, Salt Lake City, Utah, United States - GSK Investigational Site, Yakima, Washington, United States ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.gsk investigational site|phoenix|arizona|united states` — added _(2026-05-12)_ - `locations.gsk investigational site|scottsdale|arizona|united states` — added _(2026-05-12)_ - `locations.gsk investigational site|berkeley|california|united states` — added _(2026-05-12)_ - `locations.gsk investigational site|middletown|connecticut|united states` — added _(2026-05-12)_ - `locations.gsk investigational site|wilmington|delaware|united states` — added _(2026-05-12)_ - `locations.gsk investigational site|washington d.c.|district of columbia|united states` — added _(2026-05-12)_ - `locations.gsk investigational site|orlando|florida|united states` — added _(2026-05-12)_ - `locations.gsk investigational site|marietta|georgia|united states` — added _(2026-05-12)_ - `locations.gsk investigational site|smyrna|georgia|united states` — added _(2026-05-12)_ - `locations.gsk investigational site|boise|idaho|united states` — added _(2026-05-12)_ - `locations.gsk investigational site|baton rouge|louisiana|united states` — added _(2026-05-12)_ - `locations.gsk investigational site|braintree|massachusetts|united states` — added _(2026-05-12)_ - `locations.gsk investigational site|piscataway|new jersey|united states` — added _(2026-05-12)_ - `locations.gsk investigational site|new york|new york|united states` — added _(2026-05-12)_ - `locations.gsk investigational site|raleigh|north carolina|united states` — added _(2026-05-12)_ - `locations.gsk investigational site|cleveland|ohio|united states` — added _(2026-05-12)_ - `locations.gsk investigational site|oklahoma city|oklahoma|united states` — added _(2026-05-12)_ - `locations.gsk investigational site|nashville|tennessee|united states` — added _(2026-05-12)_ - `locations.gsk investigational site|bellaire|texas|united states` — added _(2026-05-12)_ - `locations.gsk investigational site|san antonio|texas|united states` — added _(2026-05-12)_ - `locations.gsk investigational site|salt lake city|utah|united states` — added _(2026-05-12)_ - `locations.gsk investigational site|yakima|washington|united states` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT00051272.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT00051272* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*